Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas

被引:0
作者
Simona Borsari
Elena Pardi
Natalia S. Pellegata
Misu Lee
Federica Saponaro
Liborio Torregrossa
Fulvio Basolo
Elena Paltrinieri
Maria Chiara Zatelli
Gabriele Materazzi
Paolo Miccoli
Claudio Marcocci
Filomena Cetani
机构
[1] University of Pisa,Department of Clinical and Experimental Medicine
[2] Helmholtz Zentrum Munchen-German Research Center for Environmental Health,Institute of Pathology
[3] University of Pisa,Department of Surgical, Medical and Molecular Pathology and Critical Area
[4] University of Ferrara,Department of Medical Sciences, Section of Endocrinology
[5] University Hospital of Pisa,Endocrine Unit 2
[6] University of Milan IRCCS Foundation Ca’ Granda Policlinico Hospital,Department of Clinical Sciences and Community Health
来源
Endocrine | 2017年 / 55卷
关键词
Primary hyperparathyroidism; MEN4; MEN1-like;
D O I
暂无
中图分类号
学科分类号
摘要
MEN1 is the main gene responsible for tumorigenesis of syndromic and sporadic primary hyperparathyroidism (PHPT). Germline mutations of the CDKN1B/p27Kip gene have been associated with multiple endocrine tumors in rats and humans. To evaluate the involvement of the CDKN1B gene and its relationship with MEN1 in sporadic PHPT, we carried out sequencing and loss of heterozygosity analyses of the CDKN1B gene in 147 sporadic parathyroid adenomas. p27 immunohistochemistry and genetic screening of the MEN1 gene were performed in 50 cases. Three germline CDKN1B variants (c.-80C>T, c.-29_-26delAGAG, c.397C>A) were identified in 3/147 patients. Reduction of CDKN1B gene transcription rate was demonstrated in vitro for the novel c.-80C>T and the c.-29_-26delAGAG variants. Loss of p27 expression was detected in the tumor carrying the c.-29_-26delAGAG variant. Two tumors carrying the CDKN1B variants also harbored a MEN1 mutation. Fifty-four percent of 50 CDKN1B mutation-negative tumors had a reduction of p27 nuclear staining. Somatic MEN1 mutations, identified in 15/50 samples, significantly segregated in tumors negative for nuclear and cytoplasmic p27 staining. The germline nature of the CDKN1B mutations suggests that they might predispose to PHPT. The lack of somatic CDKN1B mutations in our samples points to a rare involvement in parathyroid adenomas, despite the frequent loss of nuclear p27 expression. MEN1 biallelic inactivation seems to be directly related to down-regulation of p27 expression through the inhibition of CDKN1B gene transcription.
引用
收藏
页码:386 / 397
页数:11
相关论文
共 516 条
  • [21] Udelsman R(2013)Mutations in CDKN2C (p18) and CDKN2D (p19) may cause sporadic parathyroid adenoma Endocr. Relat. Cancer 20 L27-L29
  • [22] Nelson-Williams C(2000)Six novel MEN1 gene mutations in sporadic parathyroid tumors Hum. Mutat. 16 445-15563
  • [23] Lifton RP(2006)Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans Proc. Natl. Acad. Sci. U.S.A. 103 15558-64
  • [24] Carling T(2015)Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region Endocrine 49 58-560
  • [25] Starker LF(2012)Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype Eur. J. Endocrinol. 166 551-1834
  • [26] Fonseca AL(2009)Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states J. Clin. Endocrinol. Metab. 94 1826-8
  • [27] Akerstrom G(2015)Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4 (MEN4) Endocr. Connect. 4 1-1999
  • [28] Bjorklund P(2015)Early onset primary hyperparathyroidism associated with a novel germline mutation in CDKN1B Case Rep. Endocrinol. 2015 510985-5981
  • [29] Westin G(2004)A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer Cancer Res. 64 1997-6377
  • [30] Carling T(2007)Genetic variants in cell cycle control pathway confer susceptibility to lung cancer Clin. Cancer Res. 13 5974-328